Director Andrew Craig Miller files initial Form 3 at Kyverna (KYTX)

Rhea-AI Filing Summary

Kyverna Therapeutics, Inc. filed an initial Form 3 for director Andrew Craig Miller. This filing identifies him as a board member of Kyverna Therapeutics (ticker KYTX) and establishes his status as an insider subject to ongoing ownership reporting requirements.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Miller Andrew Craig

(Last) (First) (Middle)

C/O KYVERNA THERAPEUTICS, INC.

5980 HORTON ST., STE 550

(Street)

EMERYVILLE CA 94608

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
02/24/2026

3. Issuer Name and Ticker or Trading Symbol
Kyverna Therapeutics, Inc. [ KYTX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Marc Grasso, as Attorney-in-Fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the Kyverna Therapeutics (KYTX) Form 3 filed for Andrew Craig Miller show?

The Form 3 for Andrew Craig Miller shows he is a director of Kyverna Therapeutics, Inc. (KYTX). It is an initial statement of beneficial ownership, formally designating him as an insider subject to future ownership reporting.

Who is the reporting person on the Kyverna Therapeutics (KYTX) Form 3?

The reporting person is Andrew Craig Miller, listed as a director of Kyverna Therapeutics, Inc. This means he serves on the company’s board and must comply with insider reporting obligations under U.S. securities regulations.

Does the Kyverna Therapeutics (KYTX) Form 3 report any buy or sell transactions?

The Form 3 summary for Kyverna Therapeutics, Inc. shows no reported buy, sell, acquire, or dispose transactions. All transaction counts and share amounts are zero, indicating only an initial insider status filing for the director.

What is the significance of a Form 3 filing for Kyverna Therapeutics (KYTX)?

A Form 3 filing establishes an individual as a beneficial owner or insider of Kyverna Therapeutics, Inc. It marks the starting point for future ownership change reports on Forms 4 or 5, improving transparency around insider holdings.

Is Andrew Craig Miller a 10% owner of Kyverna Therapeutics (KYTX) according to the Form 3?

According to the Form 3 details, Andrew Craig Miller is listed as a director and not a ten percent owner of Kyverna Therapeutics, Inc. The “ten percent owner” flag is set to zero for this reporting person.